NCT04150497 2025-09-09
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Cellectis S.A.
Phase 1/2 Recruiting
Clinical Trials
13 trialsNCT05557903 2022-09-28
Phase â… Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL
Lanzhou Institute of Biological Products Co., Ltd
Phase 1 Unknown
NCT01982175 2022-06-21
CLL004
Shanghai Zhangjiang Biotechnology Limited Company
Phase 2 Suspended
NCT00206726 2016-08-29
ECO-1
Sanofi
Phase 2 Completed
NCT00046683 2016-07-28
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
Sanofi
Phase 3 Completed
NCT00871546 2015-08-07
SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT00923182 2015-04-30
A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Sanofi
Phase 1 Completed
NCT00077961 2015-03-26
Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL
Sanofi
Phase 1/2 Terminated
NCT00051701 2015-03-05
Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma
Sanofi
Phase 1/2 Terminated
NCT00781781 2015-02-04
Alemtuzumab Use (MabCampath®) in Hematopoietic Transplant of Unrelated Donor With Reduced Intensity Conditioning
CABYC
Phase 2 Terminated
NCT00086580 2014-03-13
Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients
Sanofi
Phase 3 Completed
NCT00328198 2014-03-13
Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia
Sanofi
Phase 2 Completed
NCT00113048 2014-02-05
Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies
Sanofi
Phase 1 Terminated